Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Little Evidence Shows Cannabis Helps Chronic Pain or PTSD

Lisa Rapaport  |  August 16, 2017

(Reuters Health)—Even though pain and posttraumatic stress disorder (PTSD) are among the most common reasons people use medical marijuana in the U.S., there isn’t much proof cannabis works for either one of these conditions, two research reviews suggest.

That’s because there hasn’t been enough high-quality research to produce conclusive evidence of the benefits or harms of cannabis for pain or PTSD, the two studies found. Both studies were conducted by a team of researchers at the Veterans Health Administration and published in Annals of Internal Medicine, online Aug. 14.1,2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The current studies highlight the real and urgent need for high-quality clinical trials in both of these areas,” says Dr. Sachin Patel, a psychiatry researcher at Vanderbilt University Medical Center in Nashville.

“If cannabis is being considered for medical use, it should certainly be after all well-established treatments have failed,” Patel says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One in 10 U.S. adults use cannabis, the researchers note. Medical marijuana is legal in 28 states and the District of Columbia, but it remains illegal under federal law.

Between 45% and 85% of people seeking medical marijuana in the U.S. do so for pain management, according to the researchers. But when they examined 27 previously published studies on this topic, they found too little information to determine whether the drug helps most types of pain.

They found only low-quality evidence that cannabis may help nerve pain, and this wasn’t for smoking pot, it was for nabiximols, oral mixtures that are sprayed into the mouth.

A separate analysis of five previous studies of cannabis for PTSD found too little data to determine whether this would help relieve symptoms.

One of the studies in the analysis focused on veterans with PTSD and found a small but statistically significant decline in symptoms for patients who started using cannabis, however, compared with people who never tried it or quit.

Among the general population, not just people with pain or PTSD, the researchers concluded cannabis may carry harms including an increased risk of car crashes, psychotic episodes and cognitive impairments.

Both studies were commissioned and funded by the Veterans Health Administration.

Curt Cashour, press secretary for the Department of Veterans Affairs, declined to make the lead study authors available for comment on their research.

In a statement about cannabis earlier this year, Dr. David Shulkin, Secretary of Veterans Affairs, says, “There may be some evidence that this is beginning to be helpful.”3

“And we’re interested in looking at that and learning from that,” Shulkin said in the May 2017 statement. “But until the time that federal law changes, we are not able to be able to prescribe medical marijuana for conditions that may be helpful.”

One area researchers are exploring is the use of cannabis to help ease mental health problems that can lead to suicide among veterans. Other conditions cannabis is used for include nausea, epilepsy, and traumatic brain injury.

Several countries, but not the U.S., have approved a cannabis-based drug to treat painful muscle spasms from multiple sclerosis.

It’s possible one group of cannabinoids may be responsible for both the high experienced by recreational users and the pain relief seen in some studies, said Dr. Winfried Hauser, a pain specialist at Klinikum Saarbrucken in Germany who wasn’t involved in the current studies.

Even though cannabis is legal for medical use in Germany, Hauser says many doctors hesitate to prescribe it because there aren’t well-defined recommended doses available. Vaporizers are difficult for many patients, and cannabis smoked in combination with tobacco can have dangerous side effects, Hauser adds.

“Medical cannabis is no magic pill,” Hauser says.


References

  1. Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: A systematic review. Ann Intern Med. 2017 Aug 15. doi: 10.7326/M17-0155. [Epub ahead of print]
  2. O’Neil ME, Nugent SM, Morasco BJ, et al. Benefits and harms of plant-based cannabis for post traumatic stress disorder: A systematic review. Ann Intern Med. 2017 Aug 15. doi: 10.7326/M17-0477. [Epub ahead of print]
  3. The White House. Office of the press secretary. News release: Press briefing by Sec. of Veterans Affairs David Shulkin. 2017 May 13.

Page: 1 2 | Multi-Page
Share: 

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:cannabisChronic painmarijuanaPainPain ManagementPost-Traumatic Stress Disorder (PTSD)

Related Articles

    Cannabis in Rheumatology Care: A Look at the Latest Research & What Rheumatologists Are Telling Their Patients

    March 26, 2018

    As medical and recreational marijuana becomes more accessible, researchers seek creative ways to study the cannabis plant and explore the complexities of the endocannabinoid system in pain relief. Rheumatologists currently face an influx of patients asking if marijuana can help them. Here’s a look at the evolving research on cannabinoids for rheumatologic pain management and how doctors are discussing it with their patients…

    Cannabis for Pain Relief: An Area Ripe for Research

    September 28, 2023

    Medical cannabis may benefit patients experiencing pain, and rheumatologists should be able to discuss its potential risks and benefits with their patients. Here are insights from Dr. Mary Ann Fitzcharles on current research, patient use and more.

    Brandon Crawford / shutterstock.com

    Case Report: Blunt Smoker Denies Tobacco Use, Delaying Diagnosis

    May 12, 2022

    Brandon Crawford / shutterstock.com Cannabis arteritis mirrors thrombo­angiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight…

    Cannabinoids Show Potential in Pain Management

    February 13, 2020

    About time / shutterstock.com ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharma­cology and therapeutics, and founding co-director of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences